CD19-CAR-DNT cells Therapy（Zhejiang Ruijiamei Biotechnologies Co Ltd）

N/A

Report date: 2024/03/05 16:11:56

Base Information

Drug NameCD19-CAR-DNT cells Therapy（Zhejiang Ruijiamei Biotechnologies Co Ltd）
Drug Alias NameCD19-CAR-DNT cellsRJMty19注射液RJMty-19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Ruijiamei Biotechnologies Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhejiang Ruijiamei Biotechnologies Co LtdWyze Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[7] 
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A